Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Reduce” from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned an average recommendation of “Reduce” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $8.20.

A number of analysts have recently weighed in on FULC shares. Truist Financial downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Friday, July 17th. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Tuesday, June 2nd. Finally, Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price for the company. in a report on Tuesday, June 2nd.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the sale, the director directly owned 10,927 shares in the company, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. bought a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at $39,000. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics during the third quarter valued at $35,000. Persistent Asset Partners Ltd purchased a new position in Fulcrum Therapeutics in the 4th quarter worth about $75,000. Summit Securities Group LLC bought a new position in Fulcrum Therapeutics during the 1st quarter valued at about $53,000. Finally, Russell Investments Group Ltd. lifted its stake in Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after acquiring an additional 9,092 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Up 1.0%

FULC opened at $3.89 on Tuesday. Fulcrum Therapeutics has a 52 week low of $2.83 and a 52 week high of $15.74. The stock has a market cap of $296.81 million, a PE ratio of -3.21 and a beta of 3.05. The business has a 50 day moving average of $3.73 and a 200-day moving average of $5.93.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Equities analysts anticipate that Fulcrum Therapeutics will post -0.69 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.